Dennis Beringer, Kuball Group, received a EU Marie Curie MSCA fellowship:
“Investigating the recognition of a novel ligand by gamma-delta T cells and the translation of this interaction into molecules for future cancer immunotherapy”.
A relevant part of the abstract:
“Gamma-delta (gd-)T cells are a fast acting subset of T cells that recognize a wide variety of ligands. In contrast to alpha-beta T cells they are not restricted to classical peptide-MHC antigens. Our preliminary data on a gd-T cell clone shows selective recognition of tumour cells mediated through a novel ligand.
The aims of this action are; 1) elucidating the molecular mechanism of the gd-T cell receptor (TCR) recognizing the novel ligand on cancer cells and 2) generating therapeutic agents for cancer cells.
A multidisciplinary approach will be used to unveil the interaction of the gd-TCR with its ligand. The results generated in this part of the action will increase the current knowledge regarding gd-T cell ligands.”